Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal Of The American Geriatrics Society 2022, 70: 2330-2343. PMID: 35499667, PMCID: PMC9378524, DOI: 10.1111/jgs.17826.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsCarcinoma, Renal CellCognitive DysfunctionDementiaHumansKidney NeoplasmsMedicare Part DUnited StatesConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaMRCC diagnosisCognitive impairmentCell carcinomaFive-year survival rateSEER-Medicare patientsMedicare Part D coveragePart D coverageMild cognitive impairmentMRCC patientsMRCC treatmentEligible patientsOlder patientsTreatment initiationKidney cancerAgent useOAA treatmentPatientsStage IVSurvival rateNew casesDiagnosisD diagnosisEvaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma
Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. Journal Of Geriatric Oncology 2022, 13: 635-643. PMID: 34996724, PMCID: PMC9232862, DOI: 10.1016/j.jgo.2021.12.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCognitive DysfunctionDementiaHumansKidney NeoplasmsMedicareUnited StatesConceptsMetastatic renal cell carcinomaNon-cancer controlsRenal cell carcinomaMRCC diagnosisMild cognitive impairmentCell carcinomaRisk factorsCognitive impairmentOlder adultsProportional hazards modelNew cancer treatmentsCohort entryOlder patientsSurgical therapyMAIN OUTCOMEExclusion criteriaAgent useDisease processHazards modelPatientsMedicare datasetCancer treatmentDiagnosisDementiaCarcinoma